it could be because it was the first country to cut its ties with the Eastern Bloc, while the case of the Czech Republic was due to its geographical location, in the center of the continent. In general, the work shows a great interconnection between European countries. Portugal, Spain and Germany have a large number of exchanges with other countries, possibly caused by factors such as tourism or by the high number of infections among their population. In this sense, Paredes emphasizes that “virus exchanges can be bidirectional. The fact that a strain from a non-European country travels to a European one may be due both to non-European people migrating to Europe, and to Europeans traveling to Europe. other continents, become infected there and return to their country with the virus.
” The study shows a great diversity of Brazil Email Lists strains in Europe, he continues, because “Europeans travel a lot but have a tendency to stay and be treated on their continent, where they enjoy good health systems.” The article The global spread 1 of HIV-1 subtype B Epidemic is published in the Journal of Molecular Epidemiology and Evolutionary Genetics of Infectious Diseases on Wednesday, June 15. It is available at this link: About IrsiCaixa The IrsiCaixa AIDS Research Institute is an organization of recognized international prestige. Its objective is to investigate HIV / AIDS and related diseases, its prevention and its treatments, with the ultimate goal of eradicating the pandemic. It was founded in 1995, as a private non-profit foundation,
by Obra Social “la Caixa” and the Department of Health of the Generalitat de Catalunya. It is located at the Germans Trias i Pujol Hospital, in Badalona (Barcelona). IrsiCaixa’s research is carried out in coordination with the most prestigious research centers in the world, and its publications have one of the highest impact factor rates in their area. More than 60 researchers dedicated to research, academic training and dissemination work at IrsiCaixa, in collaboration with healthcare professionals and more than 3,000 patients. This model facilitates the transfer of knowledge between the different actors involved and the progress towards the eradication of HIV. IrsiCaixa also participates in clinical trials to evaluate new therapeutic strategies and collaborates with developing countries in